Head of International Markets & Business Affairs, Member of the Management BoardContact us
The 24 Interpharma companies spent a total of 96 billion Swiss francs on research and development worldwide in 2017. Of this, 7 billion francs were invested in Switzerland. When compared with the sales they generated in Switzerland, the companies’ Swiss research investment was more than twice as high. According to the association, this is a testament to the great significance of Switzerland as a research location and the innovation taking place at these companies.
Investment in research and development has been especially high among companies that have their headquarters in Switzerland, such as Roche and Novartis.
Interpharma highlights the key role the pharma industry in the Swiss export sector plays. The association also notes that more than 86 patents were registered per million employees in pharmaceutical research in Switzerland between 2012 and 2016. This is more than double the number of Denmark and five times as many as in Germany.
Among the Interpharma members are companies such as Novartis, Roche, Pfizer, Astra Zeneca, Sanofi, Lilly, Johnson & Johnson, Bayer or GlaxoSmithKline.
Investments in the future
How committed the life science companies are to Basel is also reflected with regard to their planned investments which is as high as 6 billion Swiss francs. Roche, for instance, is in the process of renewing its Basel and Kaiseraugst sites. By 2023, the company with the long heritage in Basel will have invested 3 billion Swiss francs into their infrastructure. Some buildings are being modernized, while others are rebuilt completely. Bau 1, with 178 meters the tallest building in Switzerland, was opened in 2015 and cost 550 million Swiss Francs.
The remarkable tower that was designed by world-class architects Herzog & de Meuron from Basel provides workspace for approximately 2000 employees. Meanwhile, the big brother is under construction: Bau 2 will be 205 meters high and provide space for approximately 1700 employees. At the Kaiseraugst site, the group constructs an IT hub to gather all IT functions under one roof whilst taking the strategic role of technology and the growing numbers of IT employees into account. Roche will invest more than half a billion Swiss francs in Kaiseraugst.
More investments are under way in Basel:
The Swiss Tropical and Public Health Institute invests 90 millions Swiss francs in their new building in Allschwil, providing 900 workspaces. The new building is due in late 2020.
The Biozentrum of the University of Basel constructs a site for students and researchers, spending 328 million Swiss francs. Further, the University builds a Life Sciences Campus, concentrating different disciplines in one location to foster collaboration. The Department of Biosystems Science and Engineering of the ETH is also part of the project.
The University Hospital of Basel will realize a new building by 2032, costing approximately 1,2 billion Swiss francs. In 2017, the hospital opened new state-of-the-art surgery facilities.